Karyopharm Therapeutics reported $35.1M in Selling and Administration Expenses for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbott ABT:US $ 2.74B 14M
Abbvie ABBV:US $ 2.98B 99M
Acceleron Pharma XLRN:US $ 45.11M 9.64M
Amgen AMGN:US $ 1.31B 79M
Astrazeneca AZN:US 2.99B 412M
AstraZeneca AZN:LN 2.99B 412M
Avrobio Inc AVRO:US 9.58M 746K
Biocryst Pharmaceuticals BCRX:US $ 34.99M 8.67M
Bristol Myers Squibb BMY:US $ 1.79B 95M
Eli Lilly And LLY:US $ 1.58B 107.8M
Epizyme EPZM:US $ 32.79M 1.1M
GlaxoSmithKline GSK:LN 2.5B 6M
Johnson & Johnson JNJ:US $ 6B 73M
Karyopharm Therapeutics KPTI:US $ 35.1M 1.43M
Macrogenics MGNX:US $ 17.16M 1.93M
Merk MRK:US $ 2.27B 9M
Mirati Therapeutics MRTX:US $ 35.18M 5.57M
Nektar Therapeutics NKTR:US $ 29.47M 87K
Novartis NVS:US 3.6B 109M
Novartis NOVN:VX 3.6B 109M
Pfizer PFE:US $ 2.73B 61M
Regeneron Pharmaceuticals REGN:US $ 445M 30.3M
Sangamo Biosciences SGMO:US $ 14.5M 1.98M
Takeda 4502:JP 212.01B 7.83B
Tg Therapeutics TGTX:US $ 34.9M 882K
Ultragenyx Pharmaceutical RARE:US $ 53.88M 473K
Xencor XNCR:US $ 10.37M 1.51M
YTE INCY:US $ 190.7M 21.84M